Our approach provides tools to determine the extent to which resources are used for activities that prevent poor quality, that appraise the quality of products and services, and that result from internal and external failures.
Cost of Quality is much more complex than considering scraps and workforces costs. Indeed, limiting the Cost of Quality to these two cost drivers minimizes by far not only the financial spends, but also the opportunities for improvement. Pharmaceutical Companies should invest on Right First Time Quality (Quality by Design), beyond fixing issues and addressing compliance gaps. A more efficient way to look at spends for Quality should consider the cost of Compliance, the cost of Continuous Improvement, and the Cost of Poor Quality. D2C will support you to implement such an approach and install a new mindset.